IL144872A0 - Gabapentin derivative for preventing and treating visceral pain - Google Patents

Gabapentin derivative for preventing and treating visceral pain

Info

Publication number
IL144872A0
IL144872A0 IL14487200A IL14487200A IL144872A0 IL 144872 A0 IL144872 A0 IL 144872A0 IL 14487200 A IL14487200 A IL 14487200A IL 14487200 A IL14487200 A IL 14487200A IL 144872 A0 IL144872 A0 IL 144872A0
Authority
IL
Israel
Prior art keywords
preventing
visceral pain
treating visceral
gabapentin derivative
gabapentin
Prior art date
Application number
IL14487200A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL144872A0 publication Critical patent/IL144872A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14487200A 1999-02-23 2000-02-03 Gabapentin derivative for preventing and treating visceral pain IL144872A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99400440A EP1031350A1 (en) 1999-02-23 1999-02-23 Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
PCT/EP2000/001103 WO2000050027A1 (en) 1999-02-23 2000-02-03 Gabapentin derivative for preventing and treating visceral pain

Publications (1)

Publication Number Publication Date
IL144872A0 true IL144872A0 (en) 2002-06-30

Family

ID=8241887

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14487200A IL144872A0 (en) 1999-02-23 2000-02-03 Gabapentin derivative for preventing and treating visceral pain

Country Status (14)

Country Link
EP (2) EP1031350A1 (ko)
JP (1) JP2002537332A (ko)
KR (1) KR20010102314A (ko)
CN (1) CN1341018A (ko)
AU (1) AU2909800A (ko)
BR (1) BR0008323A (ko)
CA (1) CA2360528A1 (ko)
CZ (1) CZ20012982A3 (ko)
EA (1) EA200100721A1 (ko)
HK (1) HK1040198A1 (ko)
HU (1) HUP0200344A3 (ko)
IL (1) IL144872A0 (ko)
NO (1) NO20014046L (ko)
WO (1) WO2000050027A1 (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1226820A1 (en) 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
EP1902714B1 (en) * 2001-06-11 2012-01-11 XenoPort, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7420002B2 (en) 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
DE10161809A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Arzneimittel enthaltend N,N'-disubstituierte Piperazin-Verbindungen
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
US7183259B2 (en) 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
EP1541172A1 (en) * 2002-08-09 2005-06-15 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
ITMI20022658A1 (it) * 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
WO2005025562A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
AU2005301970B2 (en) 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
TWI369202B (en) 2008-01-25 2012-08-01 Xenoport Inc Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
CA2740087C (en) 2008-10-08 2019-07-23 Kyphia Pharmaceuticals, Inc. Gaba conjugates and methods of use thereof
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
IN2012DN02521A (ko) 2009-08-28 2015-08-28 Rinat Neuroscience Corp
CA2836800A1 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
BR112013029932A2 (pt) 2011-05-20 2017-01-31 Alderbio Holdings Llc composições anti-cgrp e usos das mesmas
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
WO2014113717A1 (en) 2013-01-18 2014-07-24 Ark Diagnostics, Inc. Voriconazole immunoassays
US10130715B2 (en) 2013-01-28 2018-11-20 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor
WO2014126861A1 (en) 2013-02-13 2014-08-21 Ark Diagnostics, Inc. Posaconazole immunoassays
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20200126018A (ko) 2014-03-21 2020-11-05 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CN112424158A (zh) 2018-05-14 2021-02-26 昌郁医药公司 萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
BR112020018192A2 (pt) 2019-01-08 2021-08-24 H. Lundbeck A/S Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
UA49011C2 (uk) * 1996-03-14 2002-09-16 Варнер-Ламберт Компані Похідні циклічної амінокислоти, фармацевтична композиція та спосіб лікування
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
JP2002537332A (ja) 2002-11-05
EP1031350A1 (en) 2000-08-30
HK1040198A1 (zh) 2002-05-31
NO20014046D0 (no) 2001-08-20
BR0008323A (pt) 2002-01-29
EP1154768A1 (en) 2001-11-21
WO2000050027A1 (en) 2000-08-31
HUP0200344A2 (hu) 2002-05-29
EA200100721A1 (ru) 2002-04-25
HUP0200344A3 (en) 2002-11-28
CZ20012982A3 (cs) 2002-05-15
KR20010102314A (ko) 2001-11-15
NO20014046L (no) 2001-08-20
CN1341018A (zh) 2002-03-20
CA2360528A1 (en) 2000-08-31
AU2909800A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
IL144872A0 (en) Gabapentin derivative for preventing and treating visceral pain
EP1217963A4 (en) DEVICES AND METHOD FOR TREATMENT OF TISSUE
EP1215963A4 (en) METHOD FOR THE TREATMENT OF NEUROPATHIC PAIN USING HETEROARYLMETHANSULFONAMIDES
EP1200086A4 (en) THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
IL128938A0 (en) Implantable stroke treating device
HUP0202853A3 (en) Use of retigabin for treating neuropathic pain
GB2355196B (en) Companion animal therapeutic treat
IL148166A0 (en) Drug for treating fractures
IL149939A0 (en) Iontophoretic treatment system
IL150202A0 (en) Method and composition for the treatment of pain
IL150208A0 (en) Compound and method for the treatment of pain
GB0020261D0 (en) Therapeutic treatment
GB0206401D0 (en) Side effects treatment
GB9904918D0 (en) Skin treatment
GB9907649D0 (en) Skin treatment
GB9901505D0 (en) Therapeutic treatment
GB9924980D0 (en) Therapeutic treatment
GB9913727D0 (en) Skin treatment device
GB9908993D0 (en) Treatment
GB9923343D0 (en) Treatment system
GB9809750D0 (en) Skin treatment
GB9806087D0 (en) Skin treatment
GB9903558D0 (en) Medical treatment
GB9917535D0 (en) Cosmetic treatment
SI1090554T1 (en) Device for treating meat